<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421343</url>
  </required_header>
  <id_info>
    <org_study_id>AG0074</org_study_id>
    <secondary_id>5T32AG023480-03</secondary_id>
    <nct_id>NCT00421343</nct_id>
  </id_info>
  <brief_title>Secondary Prevention of Osteoporosis</brief_title>
  <official_title>Secondary Prevention of Osteoporosis: A Window of Opportunity in the Acute Rehabilitation Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebrew Rehabilitation Center, Boston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebrew Rehabilitation Center, Boston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop and implement an evidence based protocol for the
      secondary prevention of osteoporotic fractures and falls, and to determine how compliance
      with this intervention improves muscle strength and functional status following a fracture.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a fracture, few persons are screened or treated for osteoporosis (Feldstein et al).
      It is not surprising, then, that the risk of future osteoporotic fractures remains high.
      Although little data exists on the secondary prevention of osteoporosis, calcium, vitamin D,
      and bisphosphonates have all been shown to be effective in the primary prevention of
      osteoporotic fractures, and they are likely beneficial in reducing secondary fractures as
      well. Targeting falls prevention is another approach that is likely effective in reducing the
      risk of fracture.

      In the U.S., acute rehabilitation (rehab) settings offer a unique environment to initiate
      osteoporotic therapy. Therefore, this study will develop and implement evidence based
      interventions for the secondary prevention of osteoporotic fractures in the acute rehab
      setting with the following objectives:

      Specific Aim I: Assess overall compliance with pharmacological and non-pharmacological
      interventions initiated in an acute rehab setting following a fragility fracture. Hypothesis:
      Non-compliant participants are less likely to show improvement in functional status, muscle
      strength, or vitamin D levels following the intervention.

      Specific Aim II: Describe the incidence of fragility fractures and falls in participants at
      6-months and one-year following the osteoporotic intervention introduced during acute rehab.
      Hypothesis: Similar to community based studies, a number of participants will go on to
      experience repeat falls and resulting fractures within one-year of follow-up. Compliant
      participants are less likely to experience falls and fractures.

      Specific Aim III: Confirm the high prevalence of vitamin D deficiency in a rehab setting.
      Describe the relationship between changes in vitamin D levels in participants between
      baseline and 6-month follow-up and changes in functional outcomes. Hypothesis: There will be
      a direct association between a change in vitamin D levels and a change in functional status.

      Consecutive individuals admitted with the primary or secondary diagnosis of fracture in the
      rehabilitation unit of Hebrew Rehabilitation Center will be offered enrollment. All
      participants enrolled will receive the same intervention: calcium, vitamin D, a weekly oral
      bisphosphonate, and falls prevention interventions. Specific interventions for preventing
      falls include optimization of visual acuity, a review of medications associated with falls,
      personalized exercises to improve strength and balance, and a home hazards safety evaluation
      when indicated.

      All participants will have their functional status, muscle strength, and vitamin D level
      measured at baseline during their rehab stay. At the six-month follow-up, a home visit will
      be performed for all participants to again assess functional status, muscle strength, vitamin
      D level, satisfaction with the intervention, and reasons for non-compliance. A history of
      interim falls and fractures will be collected by telephone interviews, during home nursing
      visits, and during the exit 6-month visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Adherent With the Intervention</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reasons for Non-willingness to Particiapte and Non-adherence With Intervention</measure>
    <time_frame>6 months</time_frame>
    <description>We asked participants who would not participate the primary reason for non-particiaption. We also asked participants who were not adherent with recommendations what the primary reason ws for non-adherence.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Treatment for osteoporosis and falls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention measures. No comparator group. All participants received the same intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alendronate with cholecalciferol</intervention_name>
    <description>alendronate 70mg /cholecalciferol 2800IU orally once weekly</description>
    <arm_group_label>Treatment for osteoporosis and falls</arm_group_label>
    <other_name>Fosamax Plus DÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium carbonate with cholecalciferol</intervention_name>
    <description>calcium carbonate 500mg /cholecalciferol 200IU orally twice daily</description>
    <arm_group_label>Treatment for osteoporosis and falls</arm_group_label>
    <other_name>Os-Cal with extra D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Falls prevention measures</intervention_name>
    <description>personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications</description>
    <arm_group_label>Treatment for osteoporosis and falls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to rehab unit with the primary or secondary diagnosis of fracture

          -  English speaking

          -  Cognitively able to provide consent or health care proxy available and willing to
             provide consent

          -  Willing to cooperate

        Exclusion Criteria:

          -  Pathologic or periprosthetic fractures

          -  Creatinine clearance less than 15ml/minute

          -  Severe hypocalcemia

          -  Esophageal stricture or achalasia

          -  Taking other treatment for osteoporosis besides calcium or vitamin D in the past
             6-months

          -  History of kidney stones in the past 6-months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah D Berry, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard University, Hebrew Rehabilitation Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hebrew SeniorLife</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kamel HK. Secondary prevention of hip fractures among the hospitalized elderly: are we doing enough? J Clin Rheumatol. 2005 Apr;11(2):68-71.</citation>
    <PMID>16357705</PMID>
  </reference>
  <reference>
    <citation>Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997 Sep 4;337(10):670-6.</citation>
    <PMID>9278463</PMID>
  </reference>
  <reference>
    <citation>Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998 Dec 23-30;280(24):2077-82.</citation>
    <PMID>9875874</PMID>
  </reference>
  <reference>
    <citation>Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev. 2003;(4):CD000340. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD000340.</citation>
    <PMID>14583918</PMID>
  </reference>
  <reference>
    <citation>Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med. 2003 Oct 13;163(18):2165-72.</citation>
    <PMID>14557214</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2007</study_first_posted>
  <results_first_submitted>July 8, 2010</results_first_submitted>
  <results_first_submitted_qc>May 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2011</results_first_posted>
  <last_update_submitted>May 11, 2011</last_update_submitted>
  <last_update_submitted_qc>May 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sarah D. Berry, MD, MPH</name_title>
    <organization>Harvard University, Hebrew Rehabilitation Center</organization>
  </responsible_party>
  <keyword>disease/disorder proneness/risk</keyword>
  <keyword>osteoporotic fractures</keyword>
  <keyword>accidental falls</keyword>
  <keyword>aging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Osteoporosis Medication</title>
          <description>Everyone received 1000 mg calcium per day plus vitamin D and alendronate 70mg per week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Osteoporosis Medication</title>
          <description>Everyone received 1000 mg calcium per day plus vitamin D and alendronate 70mg per week.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number Adherent With the Intervention</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Osteoporosis Medication</title>
            <description>Everyone received 1000 mg calcium per day plus vitamin D and alendronate 70mg per week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Adherent With the Intervention</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reasons for Non-willingness to Particiapte and Non-adherence With Intervention</title>
        <description>We asked participants who would not participate the primary reason for non-particiaption. We also asked participants who were not adherent with recommendations what the primary reason ws for non-adherence.</description>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Osteoporosis Medication</title>
          <description>Everyone received 1000 mg calcium per day plus vitamin D and alendronate 70mg per week.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>One subject experienced a fall resulting in a high cervical injury and death, not related to study intervention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sarah Berry</name_or_title>
      <organization>Hebrew SeiorLife</organization>
      <phone>617-971-5355</phone>
      <email>sarahberry@hrca.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

